Results published by Investigator on first-in-human biodistribution and first PET imaging results of [Ga-68]EMP-100 in metastatic renal cell carcinoma

6 Dec 2021 | [Ga-68]EMP-100, Collaborations

This first in‑human biodistribution and imaging study for 68Ga‑EMP‑100 in metastatic renal cell carcinoma independently carried out by LMU Munich, Germany, evaluated uptake characteristics in metastases and primary RCC. Conclusion: Visualization of c-MET expression...

Results published by Investigator on Image-guided Surgery in Penile Squamous Cell Carcinoma Patients

21 May 2021 | Collaborations, EMI-137

This pilot study suggest that c-MET is a promising target for fluorescence-guided tumour identification, with the potential to improve margin assessment in pSCC. The c-MET targeted approach proved to be compatible with lymphatic mapping performed in the same patient...

Results from Phase II clinical development of EMI-137 published

2 Oct 2020 | EMI-137

The work carried ou as part of Phase IIb stage of development of EMI-137 has showed FME using EMI-137 appeared to be safe andfeasible within a 1- to 3-h dose-to-imaging interval. No clinicallysignificant differences were observed among the cohorts, althougha 1-h...

Edinburgh Molecular Imaging Closes Financing

17 Dec 2019 | Press Releases

To accelerate evelopment of molecular targeted systemic radiotherapy (SR, PRRT) based on its clinical stage technology Edinburgh, United Kingdom – 17 December 2019 – Edinburgh Molecular Imaging Ltd, a company developing theragnostic agents targeting cancer, today...